Richard A. Larson to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Richard A. Larson has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.114
-
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.
Score: 0.050
-
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood. 2010 Oct 07; 116(14):2420-8.
Score: 0.021
-
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006 Sep 01; 108(5):1478-84.
Score: 0.016
-
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults. Ann Hematol. 2004; 83 Suppl 1:S103-4.
Score: 0.014
-
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002 Sep 15; 20(18):3878-84.
Score: 0.012